Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
70Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.66B | $836.30M | $2.14 |
| 2024 | $4.03B | $576.20M | $1.46 |
| 2023 | $3.62B | $541.50M | $1.44 |
| 2022 | $2.91B | $341.20M | $0.88 |
| 2021 | $2.45B | $216.90M | $0.56 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $0.66 per share
Typical surprise +5.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.70 vs $0.61beat
- Thu, Apr 30$0.56 vs $0.47beat
- Thu, Feb 12$0.68 vs $0.65beat
- Thu, Oct 30$0.61 vs $0.58beat
- Wed, Jul 30$0.48 vs $0.44beat
- Thu, May 1$0.32 vs $0.33miss
Estimates and results for DXCM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DXCM's reported EPS growth of 39.8% a year over 4 years. Historical EPS growth of 40% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $7.96
- Implied price
- $246.69
- Return from $89.75
- 22.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $122.65 — today's price is already 26.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| 20.0% | 4.5% | 9.1% | 13.0% | 16.4% | 19.5% |
| 25.0% | 8.9% | 13.6% | 17.7% | 21.3% | 24.5% |
| 30.0% | 13.2% | 18.2% | 22.4% | 26.1% | 29.5% |
| 35.0% | 17.6% | 22.7% | 27.1% | 31.0% | 34.4% |
| 40.0% | 21.9% | 27.3% | 31.8% | 35.8% | 39.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (5)
- Newszacks.com·2d ago·Positive
Here's Why DexCom (DXCM) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·2d ago·Positive
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
View source ↗ - Newszacks.com·2d ago·Positive
Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum? DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
View source ↗ - Newszacks.com·2d ago·Positive
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
View source ↗ - Newszacks.com·2d ago·Positive
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
View source ↗